FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3183571373> ?p ?o ?g. }

• W3183571373 abstract "Acute myeloid leukemia (AML) relapse after allogeneic stem cell transplant (alloSCT) remains a major therapeutic challenge. While patients with longer remission after initial alloSCT are recommended to receive cell therapy (CT) such as 2ndalloSCT or donor lymphocyte infusion (DLI), survival for patients who relapse within 6 months of alloSCT has been dismal. We evaluated the outcomes of AML relapse after alloSCT to assess the impact of different treatments on long-term survival. One hundred and seventy-two patients with AML underwent alloSCT at the Penn State Cancer Institute from January 2014 to August 2019. Sixty-nine patients relapsed (median age, 60 years; range, 10–75). Of these, 4 patients underwent 2ndalloSCT, and 26 received DLI. One-year overall survival (OS) in all cases was 20.3% (95% CI: 11.8–30.4%). Patients with ECOG performance status (PS) 0–2 at relapse showed a better 1-year OS than those with PS 3–4. Median OS for patients who received chemotherapy only or chemotherapy with CT was 74 or 173.5 days, respectively (p < 0.001). Relapsed patients receiving conventional re-induction chemotherapy were categorized as the high-intensity chemotherapy (H) group, while those receiving treatments such as hypomethylating agents or targeted agents were categorized as the low-intensity chemotherapy (L) group. The H group showed a better 1-year OS compared with the L group. Patients who received H + CT showed a better 1-year OS of 52.9% than the other 3 groups (p < 0.001). Even for patients with post-alloSCT remission duration of less than 6 months, the statistical significance was preserved. Factors including age, donor source at 1stalloSCT, time to relapse, blast counts, PS at relapse, and treatment type after post-alloSCT relapse were used for a multivariate analysis, and matched or mismatched related donor and H + CT after alloSCT were identified as independent factors associated with OS. These findings support the use of H + CT as the treatment option of choice for AML patients who relapse after alloSCT when feasible." @default.
• W3183571373 created "2021-08-02" @default.
• W3183571373 creator A5004302802 @default.
• W3183571373 creator A5009447047 @default.
• W3183571373 creator A5033927758 @default.
• W3183571373 creator A5049394650 @default.
• W3183571373 creator A5052453190 @default.
• W3183571373 creator A5055192201 @default.
• W3183571373 creator A5058677139 @default.
• W3183571373 creator A5059838967 @default.
• W3183571373 creator A5063401440 @default.
• W3183571373 creator A5065085606 @default.
• W3183571373 creator A5065589058 @default.
• W3183571373 creator A5065698591 @default.
• W3183571373 creator A5076439728 @default.
• W3183571373 creator A5079889215 @default.
• W3183571373 creator A5082458845 @default.
• W3183571373 creator A5084918260 @default.
• W3183571373 date "2021-07-29" @default.
• W3183571373 modified "2023-10-16" @default.
• W3183571373 title "Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion" @default.
• W3183571373 cites W1415829101 @default.
• W3183571373 cites W1966050525 @default.
• W3183571373 cites W2023124698 @default.
• W3183571373 cites W2036116596 @default.
• W3183571373 cites W2055033291 @default.
• W3183571373 cites W2059027705 @default.
• W3183571373 cites W2074326274 @default.
• W3183571373 cites W2109948637 @default.
• W3183571373 cites W2113946521 @default.
• W3183571373 cites W2121960517 @default.
• W3183571373 cites W2150506134 @default.
• W3183571373 cites W2172277773 @default.
• W3183571373 cites W2341077074 @default.
• W3183571373 cites W2402799752 @default.
• W3183571373 cites W2505780510 @default.
• W3183571373 cites W2559537906 @default.
• W3183571373 cites W2563816045 @default.
• W3183571373 cites W2587330838 @default.
• W3183571373 cites W2738786907 @default.
• W3183571373 cites W2770466614 @default.
• W3183571373 cites W2770885738 @default.
• W3183571373 cites W2774533007 @default.
• W3183571373 cites W2783668721 @default.
• W3183571373 cites W2800327377 @default.
• W3183571373 cites W2880011386 @default.
• W3183571373 cites W2898284215 @default.
• W3183571373 cites W2900745292 @default.
• W3183571373 cites W3048827006 @default.
• W3183571373 cites W4235603422 @default.
• W3183571373 doi "https://doi.org/10.1007/s00277-021-04616-7" @default.
• W3183571373 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34322774" @default.
• W3183571373 hasPublicationYear "2021" @default.
• W3183571373 type Work @default.
• W3183571373 sameAs 3183571373 @default.
• W3183571373 citedByCount "1" @default.
• W3183571373 countsByYear W31835713732023 @default.
• W3183571373 crossrefType "journal-article" @default.
• W3183571373 hasAuthorship W3183571373A5004302802 @default.
• W3183571373 hasAuthorship W3183571373A5009447047 @default.
• W3183571373 hasAuthorship W3183571373A5033927758 @default.
• W3183571373 hasAuthorship W3183571373A5049394650 @default.
• W3183571373 hasAuthorship W3183571373A5052453190 @default.
• W3183571373 hasAuthorship W3183571373A5055192201 @default.
• W3183571373 hasAuthorship W3183571373A5058677139 @default.
• W3183571373 hasAuthorship W3183571373A5059838967 @default.
• W3183571373 hasAuthorship W3183571373A5063401440 @default.
• W3183571373 hasAuthorship W3183571373A5065085606 @default.
• W3183571373 hasAuthorship W3183571373A5065589058 @default.
• W3183571373 hasAuthorship W3183571373A5065698591 @default.
• W3183571373 hasAuthorship W3183571373A5076439728 @default.
• W3183571373 hasAuthorship W3183571373A5079889215 @default.
• W3183571373 hasAuthorship W3183571373A5082458845 @default.
• W3183571373 hasAuthorship W3183571373A5084918260 @default.
• W3183571373 hasBestOaLocation W31835713732 @default.
• W3183571373 hasConcept C126322002 @default.
• W3183571373 hasConcept C141071460 @default.
• W3183571373 hasConcept C143998085 @default.
• W3183571373 hasConcept C194409129 @default.
• W3183571373 hasConcept C2776694085 @default.
• W3183571373 hasConcept C2777408962 @default.
• W3183571373 hasConcept C2779695342 @default.
• W3183571373 hasConcept C2911091166 @default.
• W3183571373 hasConcept C71924100 @default.
• W3183571373 hasConcept C90924648 @default.
• W3183571373 hasConceptScore W3183571373C126322002 @default.
• W3183571373 hasConceptScore W3183571373C141071460 @default.
• W3183571373 hasConceptScore W3183571373C143998085 @default.
• W3183571373 hasConceptScore W3183571373C194409129 @default.
• W3183571373 hasConceptScore W3183571373C2776694085 @default.
• W3183571373 hasConceptScore W3183571373C2777408962 @default.
• W3183571373 hasConceptScore W3183571373C2779695342 @default.
• W3183571373 hasConceptScore W3183571373C2911091166 @default.
• W3183571373 hasConceptScore W3183571373C71924100 @default.
• W3183571373 hasConceptScore W3183571373C90924648 @default.
• W3183571373 hasLocation W31835713731 @default.
• W3183571373 hasLocation W31835713732 @default.
• W3183571373 hasOpenAccess W3183571373 @default.
• W3183571373 hasPrimaryLocation W31835713731 @default.
• W3183571373 hasRelatedWork W1961611968 @default.

• next